caplacizumab-yhdp
| Brand name | Cablivi |
|---|---|
| Active ingredient | caplacizumab-yhdp |
| Strength | 11MG |
| Dosage form | For injection |
| Route | Intravenous, Subcutaneous |
| Modality | Biologic |
| FDA approval | February 2019 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.